Celgene Corporation (CELG)
-NasdaqGS 122.58 
1.06(0.86%) 4:00PM EDT|After Hours
:
122.58 0.00 (0.00%) 4:20PM EDT - Nasdaq Real Time Price
| Prev Close: | 123.64 |
|---|
| Open: | 123.34 |
|---|
| Bid: | 121.01 x 1000 |
|---|
| Ask: | 123.08 x 200 |
|---|
| 1y Target Est: | 134.63 |
|---|
| Beta: | 0.92 |
|---|
| Next Earnings Date: | 25-Jul-13 |
|---|
| Day's Range: | 121.66 - 123.71 |
|---|
| 52wk Range: | 58.53 - 131.82 |
|---|
| Volume: | 2,286,520 |
|---|
| Avg Vol (3m): | 3,213,210 |
|---|
| Market Cap: | 51.13B |
|---|
| P/E (ttm): | 37.29 |
|---|
| EPS (ttm): | 3.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Glance: Biotechnology companiesAP(Fri 6:03PM EDT)
- [video] Nasdaq Check: Valeant-Bausch & Lomb Deal?at CNBC(Fri 1:30PM EDT)
- Midday Glance: Biotechnology companiesAP(Fri 1:17PM EDT)
- Investing In Cancer Research Is Worth The Risk: Echo Heat Seeking Alpha(Fri 11:59AM EDT)
- Encouraging News for Peregrine PharmaZacks(Fri 11:10AM EDT)
- Early Glance: Biotechnology companiesAP(Fri 10:33AM EDT)
- Priority FDA Review for Celgene's AbraxaneZacks(Fri 10:30AM EDT)
- Celgene, Gilead, and Biogen could go much higher, says Bernsteinat theflyonthewall.com(Fri 7:20AM EDT)
- 4 Healthcare Stock Stories Prescribed For Investorsat Wall St. Cheat Sheet(Thu, May 23)
- NPS Pharma Prices OfferingZacks(Thu, May 23)
- Amgen Stock Checkup for Mayat Motley Fool(Thu, May 23)
- 5 Stocks Raising The Drugs Industry Higherat TheStreet(Thu, May 23)
- Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic CancerBusiness Wire(Thu, May 23)
- Jim Cramer: Buy Biogen Idec, Celgene, Clean Harbors, and This Stockat Wall St. Cheat Sheet(Thu, May 23)
- McDonald’s Initiates a Dividend, Seagate Gets An Upgrade, and 3 More Hot Stocksat Wall St. Cheat Sheet(Thu, May 23)
Key Statistics
| Forward P/E (1 yr): | 17.77 |
|---|
| P/S (ttm): | 9.05 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 5.75 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 1.43 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | 0.97 |
|---|
Business Summary
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and immune-inflammatory related diseases in the United States, Europe, and other countries.
View More